left-arrow right-arrow pinterest facebook google_plus linkedin

Skin Cancer Trials

The following listings are our current trials. If you have questions or want to learn more about the trial, please contact us and provide the Methodist Health System Trial Code listed with the description.

Alliance A091802

Status: Recruiting | Phase II

Official Title: Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer

Study Purpose: The purpose of this study is to test the good and bad effects of the combined treatment, using the drugs cetuximab and avelumab as well as avelumab by itself. Learn more


Status: Suspended | Phase I

Official Title: A Sequential 2-Arm, Open-Label Phase 1 Study to Evaluate the Effects of Encorafenib in Combination with Binimetinib on the Pharmacokinetics of Losartan, Midazolam, Caffeine, Omeprazole, and Dextromethorphan Administered in a Cocktail Approach and on the Pharmacokinetics of Rosuvastatin in Patients with BRAF V600-Mutant Unresectable or Metastatic Melanoma or Other Advanced Solid Tumors

Study Purpose: The main purpose of this study is to look at the effect of encorafenib and binimetinib (the study drugs) on the activity of other common drugs.  The study will also look at safety and how participants tolerate the study drugs when given with the other common drugs. Learn more


Status: Recruiting | Phase III

Official Title: Testing Therapy Sequence for Advanced BRAF Mutation Melanoma

Study Purpose: The purpose of this study to compare the good and bad effects of the sequence of immunotherapy followed by BRAF inhibitor therapy if and when it gets worse. Learn more


Status: Recruiting | Phase II/III 

Official Title: Randomized phase II/III study of nivolumab plus ipilimumab plus sargramostim versus nivolumab plus ipilimumab in patients with unresectable stage III or stage IV melanoma

Study Purpose: To compare any good and bad effects of giving three drugs- ipilimumab, nivolumab, and sargramostim at the same time compared to just ipilimumab and nivolumab together. Learn more


Status: Recruiting | Phase III

Official Title: Testing Pembrolizumab versus Observation in Patients with Merkel Cell Carcinoma after Surgery

Study Purpose: This study is being done to see if the chance of cancer growing back can be lowered by adding the study drug, pembrolizumab, after surgery. Learn more.

Regeneron R2810-ONC-1788

Status: Recruiting | Phase III

Official Title: A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab Versus Placebo after Surgery and Radiation Therapy in Patients with High Risk Cutaneous Squamous Cell Carcinoma (CSCC)

Study Purpose: To determine if cemiplimab will prevent CSCC from returning after surgery and radiation. The researchers also want to find out if cemiplimab will help people live longer, how study participation affects how people feel, and side effects that people may experience during the study. Learn more.

SWOG S1801

Status: Recruiting | Phase II

Official Title: A phase II randomized study of adjuvant vs. neoadjuvant MK-3475 (Pembrolizumab) for clinically detectable stage III-IV high-risk melanoma

Study Purpose: The purpose of this study is to compare outcomes of receiving the study drug either before and after or only after surgery for your type of cancer. Learn more

Regeneron R2810-ONC-1901

Status: Recruiting | Phase II

Official Title: A Phase 2 Study of Neoadjuvant Cemiplimab For Stage II To IV (M0) Cutaneous Squamous Cell Carcinoma

Study Purpose: To see if cemiplimab can eliminate or reduce the number of living cancer cells in tumor(s) if taken before surgery. Learn more